Journal
CANCER CELL
Volume 37, Issue 4, Pages 496-513Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2020.03.009
Keywords
-
Categories
Funding
- UTSW Simmons Cancer Center [P30 CA142543]
- CPRIT [RR170061]
- NCI Breast SPORE [P50 CA098131]
- Susan G. Komen Breast Cancer Foundation [SAC100013]
- Breast Cancer Research Foundation
- NCI [R01CA224899]
Ask authors/readers for more resources
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype. Treatment of ER+ breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as endocrine therapy). While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge. An increasing number of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment. Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available